HAVCR2 and neoplasm: Indeed, antibodies targeting CTLA-4 or TIM-3 have been shown to be effective in various mouse tumour models when administered early (day 3 post-inoculation) but are largely ineffective against established tumours (day 11 post-inoculation) (113).